Transport
NPI deactivated
Regional West Medical Center
Regional West Medical Center was paid $15.11M by Medicaid between Jan 2018 and Dec 2024, across 257 billing codes. Its largest line is 99284, emergency room visit (serious) — 9.7% of everything it billed.
33Billing provider infoREGIONAL WEST MEDICAL CENTER
SCOTTSBLUFF, NE 69361
SCOTTSBLUFF, NE 69361
33aNPI1639101199assigned 07/07/2006
33bProvider typeLand Ambulance
28Total paid$15.11M
24GClaims457,770
24DCodes billed257
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Land Ambulance providers in Nebraska
Rank by total paid#1 of 31
Median peer was paid$48K
This provider vs. median315×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RESCH, NED controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 63,698 | $2.50M | |
| 2019 | 63,416 | $2.67M | |
| 2020 | 57,781 | $1.71M | |
| 2021 | 101,297 | $2.94M | |
| 2022 | 108,373 | $3.22M | |
| 2023 | 46,540 | $1.50M | |
| 2024incomplete | 16,665 | $579K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.7% | 10,951 | 9,797 | $1.47M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 9.4% | 5,425 | 5,122 | $1.43M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.4% | 9,075 | 8,480 | $1.27M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.4% | 1,894 | 1,758 | $820K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 4.9% | 1,733 | 1,680 | $739K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.4% | 4,288 | 3,845 | $664K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.3% | 2,359 | 2,003 | $643K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.1% | 1,886 | 1,717 | $475K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 9,628 | 3,076 | $461K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.9% | 5,528 | 1,498 | $445K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.5% | 5,543 | 2,011 | $372K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 3,279 | 1,892 | $331K |
245 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.2% | 457 | $327K |
| G0378 | Hospital observation service, per hour | 1.6% | 2,413 | $236K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.5% | 1,167 | $226K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 496 | $204K |
| 80053 | Comprehensive metabolic panel | 1.3% | 32,537 | $200K |
| A0425 | Ground mileage, per statute mile | 1.3% | 2,755 | $191K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 13,742 | $167K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.1% | 4,794 | $164K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,043 | $149K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 35,777 | $145K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,788 | $142K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 382 | $139K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 846 | $128K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 340 | $127K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,598 | $120K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,138 | $118K |
| A4649 | Surgical supply; miscellaneous | <1% | 5,837 | $117K |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 988 | $114K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,917 | $105K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,235 | $105K |
| 0099U | <1% | 616 | $101K | |
| 97161 | <1% | 1,651 | $95K | |
| 97113 | <1% | 965 | $74K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 281 | $72K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,634 | $72K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,752 | $68K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,496 | $67K |
| 87486 | <1% | 1,731 | $65K | |
| 87581 | <1% | 1,731 | $65K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,272 | $63K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,682 | $60K |
| 80061 | Lipid panel | <1% | 7,570 | $60K |
| 84439 | <1% | 6,238 | $57K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 999 | $56K |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,868 | $56K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 258 | $55K |
| 87088 | <1% | 8,779 | $55K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 783 | $48K |
| 85027 | <1% | 7,150 | $46K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,692 | $43K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 781 | $43K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,243 | $42K |
| 87507 | <1% | 118 | $38K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,945 | $38K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,057 | $37K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,865 | $36K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,956 | $35K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,676 | $35K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,987 | $33K |
| 74018 | <1% | 671 | $33K | |
| 83655 | <1% | 1,955 | $32K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,488 | $29K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 487 | $27K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 999 | $26K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,450 | $26K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 50 | $26K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 341 | $26K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,296 | $25K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,728 | $24K |
| 82607 | <1% | 2,364 | $23K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,730 | $23K |
| 86850 | <1% | 1,599 | $23K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,292 | $22K |
| 97165 | <1% | 197 | $22K | |
| 84702 | <1% | 1,238 | $20K | |
| 87186 | <1% | 3,713 | $18K | |
| 87077 | <1% | 3,845 | $18K | |
| 86140 | <1% | 2,980 | $18K | |
| 82728 | <1% | 1,898 | $17K | |
| J3490 | Unclassified drugs | <1% | 10,503 | $17K |
| 87660 | <1% | 1,677 | $17K | |
| 80081 | <1% | 306 | $16K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 350 | $16K |
| 83013 | <1% | 221 | $16K | |
| 87081 | <1% | 1,567 | $16K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 41 | $15K |
| 93975 | <1% | 75 | $15K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,063 | $14K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 43 | $14K |
| 83550 | <1% | 1,610 | $13K | |
| 87480 | <1% | 1,664 | $12K | |
| 86592 | <1% | 1,308 | $12K | |
| 83970 | <1% | 423 | $12K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 820 | $12K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,850 | $12K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 121 | $12K |
| 86703 | <1% | 945 | $11K | |
| 97803 | <1% | 212 | $11K | |
| 87340 | <1% | 1,152 | $11K | |
| 86900 | <1% | 1,592 | $11K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,344 | $11K |
| 87510 | <1% | 1,664 | $11K | |
| 84484 | <1% | 2,857 | $11K | |
| 83690 | <1% | 3,532 | $10K | |
| 85610 | <1% | 4,205 | $10K | |
| 87070 | <1% | 1,534 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,628 | $10K |
| 86870 | <1% | 423 | $10K | |
| 83880 | <1% | 1,058 | $10K | |
| 85652 | <1% | 2,385 | $10K | |
| 81001 | <1% | 6,081 | $10K | |
| 0097U | <1% | 74 | $9K | |
| 81003 | <1% | 5,917 | $9K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 54 | $9K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 2,988 | $8K |
| 83735 | <1% | 3,317 | $8K | |
| 76937 | <1% | 340 | $8K | |
| 83540 | <1% | 1,662 | $8K | |
| A9270 | Non-covered item or service | <1% | 14,517 | $8K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 173 | $7K |
| 86762 | <1% | 747 | $7K | |
| 76642 | <1% | 44 | $6K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 14 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 984 | $6K |
| 87430 | <1% | 432 | $6K | |
| 90686 | <1% | 477 | $6K | |
| 81025 | <1% | 1,568 | $5K | |
| 87084 | <1% | 242 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 223 | $5K |
| 82950 | <1% | 835 | $5K | |
| 12001 | <1% | 13 | $5K | |
| 88342 | <1% | 642 | $5K | |
| 97162 | <1% | 55 | $5K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 318 | $5K |
| 87205 | <1% | 1,071 | $5K | |
| 86038 | <1% | 480 | $5K | |
| 87400 | <1% | 303 | $4K | |
| 82570 | <1% | 1,288 | $4K | |
| 86803 | <1% | 464 | $4K | |
| 84156 | <1% | 1,103 | $4K | |
| 84153 | <1% | 376 | $4K | |
| 84481 | <1% | 253 | $4K | |
| 88142 | <1% | 205 | $4K | |
| 83516 | <1% | 412 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 947 | $3K |
| 86376 | <1% | 199 | $3K | |
| 82962 | <1% | 2,747 | $3K | |
| 95819 | <1% | 13 | $3K | |
| 84550 | <1% | 972 | $3K | |
| 86431 | <1% | 287 | $3K | |
| 97802 | <1% | 37 | $3K | |
| 90715 | <1% | 208 | $3K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 21 | $3K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 17 | $3K |
| 85379 | <1% | 1,254 | $3K | |
| 72100 | <1% | 91 | $3K | |
| 82043 | <1% | 904 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,256 | $2K |
| 84146 | <1% | 270 | $2K | |
| 80069 | <1% | 433 | $2K | |
| 72141 | <1% | 15 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 604 | $2K |
| 90734 | <1% | 93 | $2K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 15 | $2K |
| 87040 | <1% | 947 | $2K | |
| 82746 | <1% | 243 | $2K | |
| 92526 | <1% | 39 | $2K | |
| 76536 | <1% | 12 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 50 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 230 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 177 | $1K |
| 82784 | <1% | 113 | $1K | |
| 97116 | <1% | 59 | $1K | |
| 97014 | <1% | 31 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 470 | $1K |
| 85730 | <1% | 719 | $1K | |
| 90651 | <1% | 77 | $1K | |
| 73564 | <1% | 15 | $974.55 | |
| 83605 | <1% | 702 | $950.76 | |
| 86225 | <1% | 147 | $937.21 | |
| 71250 | <1% | 15 | $931.36 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,727 | $910.86 |
| 82150 | <1% | 195 | $910.68 | |
| 82947 | <1% | 217 | $877.93 | |
| 93246 | <1% | 13 | $849.73 | |
| 86235 | <1% | 135 | $835.22 | |
| 83001 | <1% | 76 | $670.84 | |
| 86160 | <1% | 164 | $546.31 | |
| 96376 | <1% | 50 | $528.98 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 99 | $505.91 |
| 97035 | <1% | 26 | $505.25 | |
| 94060 | <1% | 12 | $500.93 | |
| A4315 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way, all silicone | <1% | 258 | $407.49 |
| 86003 | <1% | 50 | $407.09 | |
| 84703 | <1% | 122 | $387.03 | |
| 82670 | <1% | 41 | $353.42 | |
| 82247 | <1% | 60 | $302.07 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 259 | $299.12 |
| 80076 | <1% | 44 | $298.33 | |
| 81513 | <1% | 15 | $276.70 | |
| 82785 | <1% | 13 | $269.23 | |
| 86901 | <1% | 75 | $258.41 | |
| 84403 | <1% | 14 | $252.02 | |
| 86706 | <1% | 25 | $236.13 | |
| 87807 | <1% | 19 | $218.68 | |
| 84480 | <1% | 14 | $194.74 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13 | $184.47 |
| 82550 | <1% | 34 | $176.88 | |
| 73630 | <1% | 13 | $174.86 | |
| 73030 | <1% | 14 | $171.44 | |
| 80074 | <1% | 12 | $167.16 | |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 28 | $166.66 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 187 | $163.49 |
| 82077 | <1% | 969 | $127.95 | |
| 81015 | <1% | 205 | $125.02 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $119.17 |
| 84145 | <1% | 55 | $115.74 | |
| 84100 | <1% | 33 | $93.98 | |
| 80179 | <1% | 440 | $73.72 | |
| 87210 | <1% | 12 | $64.02 | |
| 90653 | <1% | 27 | $63.01 | |
| 83615 | <1% | 40 | $63.00 | |
| 80164 | <1% | 13 | $60.20 | |
| 90633 | <1% | 13 | $58.50 | |
| 88304 | <1% | 12 | $53.27 | |
| 82565 | <1% | 20 | $51.70 | |
| 80143 | <1% | 457 | $36.88 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 212 | $17.31 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 318 | $17.07 |
| G0008 | Administration of influenza virus vaccine | <1% | 190 | $5.67 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,760 | $4.84 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 17 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 119 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 215 | $0.00 |
| A7000 | Canister, disposable, used with suction pump, each | 0% | 104 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 28 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 15 | $0.00 |
| C1729 | Catheter, drainage | 0% | 118 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 48 | $0.00 |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | 0% | 55 | $0.00 |
| A7002 | Tubing, used with suction pump, each | 0% | 148 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 14 | $0.00 |
| 97602 | 0% | 15 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 12 | $0.00 |
| 3044F | 0% | 26 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 206 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 157 | $0.00 |
| C1769 | Guide wire | 0% | 66 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 155 | $0.00 |
| 82803 | 0% | 33 | $0.00 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 122 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 35 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRESCH, NED (CEO)
| Provider | Location | Paid |
|---|---|---|
| Regional West Physicians Clinic | Scottsbluff, NE | $8.98M |
| Regional West Medical Center | Scottsbluff, NE | $1.75M |
| Regional West Medical Center | Scottsbluff, NE | $1.41M |
| Regional West Medical Center | Cheyenne, WY | $63K |
| Sterling Regional Medcenter | Sterling, CO | $10K |
| Regional West Medical Center | Denison, IA | $7K |
| Regional West Physicians Clinic | Morrill, NE | $6K |
| Regional West Medical Center | Casper, WY | $5K |
| Regional West Medical Center | Norfolk, NE | $1K |
| Regional West Medical Center | Ida Grove, IA | $1K |
| Regional West Medical Center | Rapid City, SD | $815.11 |
| Regional West Medical Center | Scottsbluff, NE | $671.14 |
| Regional West Medical Center | Council Bluffs, IA | $27.70 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.